What are the strengths and weaknesses of the ASTRUM‑006 trial compared with the Matterhorn trial?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Comparison of ASTRUM-006 and MATTERHORN Trials

Both ASTRUM-006 and MATTERHORN demonstrated significant event-free survival benefits with perioperative immunotherapy in resectable gastric/gastroesophageal junction cancer, but MATTERHORN provides stronger global evidence with broader applicability, while ASTRUM-006 offers a chemotherapy-sparing adjuvant approach specifically for PD-L1-positive patients.

Trial Design and Population

MATTERHORN Trial 1

  • Design: Global, double-blind, placebo-controlled phase III trial
  • Population: 948 patients (474 per arm) with resectable gastric/GEJ adenocarcinoma, unselected for PD-L1 status
  • Geographic scope: Multinational (Western and Asian countries)
  • Treatment: Durvalumab + FLOT (4 cycles perioperative) followed by durvalumab maintenance (10 cycles)
  • Median follow-up: 31.5 months

ASTRUM-006 Trial 2

  • Design: Double-blind, multicentre phase III trial
  • Population: 588 patients (292 vs 296) with PD-L1 CPS ≥5 resectable gastric/GEJ adenocarcinoma
  • Geographic scope: Primarily China (57 hospitals) plus Thailand
  • Treatment: Serplulimab + SOX (3 cycles neoadjuvant) followed by serplulimab maintenance (17 cycles) vs SOX (3 cycles neoadjuvant + 5 cycles adjuvant)
  • Median follow-up: 35.9 months (ITT population)

Efficacy Outcomes

Event-Free Survival

MATTERHORN 1:

  • 2-year EFS: 67.4% vs 58.5% (HR 0.71,95% CI 0.58-0.86, P<0.001)
  • Benefit observed across unselected population

ASTRUM-006 2:

  • Median EFS in ITT (CPS ≥5): Not reached vs 35.9 months (HR 0.73,95% CI 0.56-0.94, P=0.015)
  • Median EFS in CPS ≥10: Not reached vs 42.0 months (HR 0.65,95% CI 0.47-0.90, P=0.0082)
  • Advantage: Greater benefit in higher PD-L1 expression subgroup

Overall Survival

MATTERHORN 1:

  • 2-year OS: 75.7% vs 70.4%
  • Piecewise HR: 0.99 (months 0-12) and 0.67 (≥12 months), P=0.03
  • Weakness: Did not meet prespecified significance threshold (P<0.0001)

ASTRUM-006 2:

  • OS data pending extended follow-up
  • Weakness: Immature survival data at current analysis

Pathological Complete Response

MATTERHORN 1:

  • pCR: 19.2% vs 7.2% (RR 2.69,95% CI 1.86-3.90)
  • Advantage: Nearly 3-fold improvement

ASTRUM-006 2:

  • pCR data not reported in available evidence

Safety Profile

MATTERHORN 1

  • Grade 3-4 treatment-related AEs: 71.6% vs 71.2%
  • Delayed surgery: 10.1% vs 10.8%
  • Delayed adjuvant treatment: 2.3% vs 4.6%
  • Advantage: No increase in perioperative complications with immunotherapy

ASTRUM-006 2

  • Grade ≥3 treatment-related AEs: 47% vs 59%
  • Treatment discontinuation due to AEs: 7% vs 11%
  • Advantage: Lower toxicity profile, potentially due to chemotherapy-sparing adjuvant phase

Key Strengths and Weaknesses

MATTERHORN Strengths 1, 3, 4

  1. Global applicability: First multinational phase III evidence for perioperative immunotherapy in this setting
  2. Unselected population: No biomarker requirement increases accessibility
  3. Established chemotherapy backbone: FLOT is Western standard of care per FLOT4 trial 5
  4. Robust EFS benefit: Statistically significant primary endpoint
  5. Surgical feasibility: No increase in perioperative complications

MATTERHORN Weaknesses 1, 4

  1. OS data immature: Did not meet stringent prespecified significance threshold
  2. Intensive chemotherapy: FLOT regimen more toxic than Asian standards
  3. Treatment burden: 4 cycles perioperative chemotherapy plus 10 cycles immunotherapy maintenance
  4. No biomarker enrichment: Cannot identify patients most likely to benefit

ASTRUM-006 Strengths 2

  1. Biomarker-selected population: PD-L1 CPS ≥5 enrichment likely enhances benefit
  2. Superior safety profile: Lower grade ≥3 AEs (47% vs 59%)
  3. Chemotherapy-sparing adjuvant: Only immunotherapy maintenance after surgery reduces cumulative chemotherapy exposure
  4. Longer follow-up: 35.9 months provides more mature EFS data
  5. Greater EFS benefit in CPS ≥10: HR 0.65 suggests stronger effect in biomarker-high patients

ASTRUM-006 Weaknesses 2

  1. Geographic limitation: Primarily Chinese population limits generalizability
  2. Biomarker requirement: PD-L1 testing mandatory, excludes CPS <5 patients
  3. Non-standard chemotherapy backbone: SOX not established Western standard (though validated in Asian RESOLVE trial 5)
  4. OS data pending: Cannot confirm survival benefit yet
  5. Smaller sample size: 588 vs 948 patients provides less statistical power

Clinical Context and Implications

Guideline Perspective 5

Current guidelines weakly recommend perioperative chemotherapy or neoadjuvant chemoradiotherapy for resectable advanced esophagogastric junction cancer, with regional variations (Western: perioperative FLOT; Asian: surgery + adjuvant chemotherapy). Both trials advance this paradigm by integrating immunotherapy.

Comparative Trial Context 4

Critical distinction: KEYNOTE-585 (pembrolizumab + cisplatin/5-FU) failed to meet its primary EFS endpoint despite trends toward improvement, while MATTERHORN succeeded. This suggests the chemotherapy backbone and immunotherapy agent selection matter significantly.

Practical Decision Algorithm

For Western/International Practice:

  • First choice: MATTERHORN regimen (durvalumab + FLOT) 1
    • Rationale: Global evidence, unselected population, established FLOT backbone
    • Use regardless of PD-L1 status

For Asian Practice:

  • If PD-L1 CPS ≥5: Consider ASTRUM-006 regimen (serplulimab + SOX) 2
    • Rationale: Superior safety, chemotherapy-sparing adjuvant, validated SOX backbone in Asia
  • If PD-L1 CPS <5 or unknown: MATTERHORN approach remains option
    • Alternative: Standard perioperative SOX per RESOLVE trial 5

Key Caveats:

  1. Both trials require extended OS follow-up to confirm survival benefit
  2. PD-L1 testing should be performed when feasible to identify patients most likely to benefit from ASTRUM-006 approach
  3. Neither trial addresses HER2-positive disease (requires trastuzumab integration per ToGA trial 5)
  4. Surgical quality and timing remain critical—neither regimen should delay appropriate surgery

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.